Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.60 |
| ▸ | CTSB | P07858 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.41 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.41 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620476 | 1.00 | AR (0.60) | ARCTSBALDH1A1LMNAMAPT | |
| SCHEMBL3619196 | 0.85 | AR (0.61) | ARCTSBMAPTHTTGAA | |
| SCHEMBL3619197 | 0.85 | AR (0.61) | ARCTSBMAPTHTTGAA | |
| SCHEMBL6195201 | 0.84 | MAPT (0.60) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL6197167 | 0.84 | MAPT (0.60) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL6196541 | 0.84 | MAPT (0.60) | ALDH1A1LMNAMAPTHTTSMN1; SMN2 | |
| SCHEMBL2711827 | 0.81 | CTSB (0.75) | ARCTSBALDH1A1LMNAMAPT | |
| SCHEMBL3622442 | 0.79 | AR (0.49) | ARCTSBALDH1A1LMNAMAPT | |
| SCHEMBL4247507 | 0.78 | HTR2C (0.45) | ALDH1A1LMNAMAPT | |
| SCHEMBL4247502 | 0.78 | HTR2C (0.45) | ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | CEPA SCHWARZ PHARMA, S.L. (ES) | 2009-02-05 | — | — | US | disclosed |
| EP-1830854-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | Schwarz Pharma, s.l. (ES) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006069993-A1 | ARYLPIPERAZINE DERIVATIVES AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | SCHWARZ PHARMA S.L. (ES) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036455-A1 | ARYLPIPERAZINE DERIVATIVE AND USE THEREOF AS 5-HT1A RECEPTOR LIGANDS | HTR1A, HTR5A, HTR2C | AR 380/4885CTSB 743/4885ALDH1A1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.